Galectin Therapeutics (GALT) Misses Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16).
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- A.O. Smith executive chairman to retire, CEO to assume chairman role
- Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
